Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

Zev A. Wainberg,Johanna C. Bendell,Heinz-Josef Lenz,Ari David Baron,Jordan Berlin,Alberto Bessudo,Daniel Bruetman,Ki Y Chung,Haeseong Park,Manish R. Patel,Adeboye H. Adewoye,JieJane Liu,Ravindranath Patel,Manish A. Shah

Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

2018

Zev A. Wainberg
Johanna C. Bendell
Heinz-Josef Lenz
Ari David Baron
Jordan Berlin
Alberto Bessudo
Daniel Bruetman
Ki Y Chung
Haeseong Park
Manish R. Patel
Adeboye H. Adewoye
JieJane Liu
Ravindranath Patel
Manish A. Shah

3578Background: Matrix metalloproteinase 9 is highly expressed in several malignancies, including metastatic colorectal cancer (mCRC) and is an adverse prognostic feature. In preclinical colorectal...

Keywords:

FOLFIRI
Bevacizumab
Pathology
Cancer research
Colorectal cancer
Medicine
second line
in patient
Oncology
phase i study
Internal medicine
matrix metalloproteinase 9

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations